![]() Medical writing support, under the direction of the author, was provided by ApotheCom and supported by Bayer Consumer Care AG, Basel, Switzerland, in accordance with Good Publication Practice (Ann Intern Med.When you have supported artists such as Alesso, Steve Aoki, Bassjackers, CAZZETTE, Starkillers, Deniz Koyu, Felix Cartal, EDX, 3LAU, DJ B元ND and Candyland, you know your time has come. The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this abstract. ![]() The CANDELA study was funded by Regeneron Pharmaceuticals, Inc. Paolo Lanzetta: Consultant for Aerie, Allergan, Apellis, Bayer, Biogen, Centervue, Novartis, Outlook Therapeutics, and Roche In this study, we observed anatomic and functional improvements with IVT-AFL 8 mg, suggesting potential additional therapeutic benefit in comparison to IVT-AFL 2 mg in patients with nAMD. The overall safety of IVT-AFL 8 mg was similar to that of IVT-AFL 2 mg. Eyes in the IVT-AFL 8 mg versus IVT-AFL 2 mg group showed a greater reduction from baseline in median central subfield thickness (−162 µm vs −88 µm), and a numerically higher increase from baseline in mean BCVA (+7.9 vs +5.1 letters nominal P=0.1957) at Week 44. The proportion of eyes with no retinal fluid in the center subfield was 50.9% (27/53) for the IVT-AFL 8 mg group and 34.0% (18/53) for the IVT-AFL 2 mg group (treatment difference, 17.0% P=0.0770) at Week 16 and 39.6% (21/53) and 28.3% (15/53), respectively (treatment difference, 11.3% nominal P=0.2185) at Week 44. No new safety signals were identified no serious events of intraocular inflammation, nor events of occlusive vasculitis or anti-platelet trialists' collaboration (APTC)-defined arterial thromboembolic were reported through Week 44. The incidence of ocular adverse events (AEs) through Week 44 was 37.7% (20/53) for the IVT-AFL 8 mg group and 37.7% (20/53) for the IVT-AFL 2 mg group. Overall, a greater proportion of patients were female (62.3%) the mean (standard deviation ) age was 77.4 (8.0) years and mean (SD) baseline BCVA was 58.0 (12.1) letters. The primary endpoints were safety and the proportion of eyes without retinal fluid in the center subfield at Week 16. A total of 106 patients were randomized 1:1 to receive 3 monthly doses of either IVT-AFL 8 mg (n=53) or IVT-AFL 2 mg (n=53) followed by doses at Weeks 20 and 32. ![]() Treatment-naïve patients (≥50 years old) with active subfoveal choroidal neovascularization secondary to nAMD and a best corrected visual acuity (BCVA) of 78 to 24 letters (approximately 20/32 to 20/320) in the study eye were enrolled. The phase 2 CANDELA trial assessed the safety and efficacy of IVT-AFL 8 mg versus IVT-AFL 2 mg in patients with neovascular age-related macular degeneration (nAMD).ĬANDELA was a phase 2, randomized, single-masked, open-label, 44-week clinical trial (NCT04126317) that was conducted across 46 sites in the United States between November 2019 and November 2021. Preclinical experiments have previously shown that a high dose of intravitreal aflibercept (IVT AFL) resulted in prolonged efficacy in a representative model system compared with the equivalent of IVT-AFL 2 mg, the currently indicated dose.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |